LAVA Therapeutics NV
DelistedCIK 1840748fmd_00RZJGJ77HFGPSE3NZH31BVESEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2025, 12 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Total revenues | – | 4 | 5 | 19 | 7 | 12 |
| Cost of revenue | – | – | – | – | 3 | – |
| Gross profit | – | – | 5 | 19 | 3 | – |
| Research and development | 8 | 16 | 37 | 40 | 33 | 28 |
| Operating income | (10) | (15) | (44) | (35) | (43) | (30) |
| Interest expense | 0 | 0 | 1 | – | 0 | 1 |
| Interest and investment income | – | – | – | – | 4 | 4 |
| Other non-operating income (expense) | – | – | – | – | 2 | 5 |
| Income before taxes | (10) | (16) | (42) | (32) | (42) | (24) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | – | (16) | (42) | (32) | (42) | (25) |
| Net income | (10) | (16) | (42) | (32) | (42) | (25) |